Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 31, 2021, the Company entered into a Supplementary Agreement with
the Company's Executive Vice President Zhigong Lin to appoint Lin as the Chief
Executive Officer of GOF Biotechnologies, Inc.("GOF"), a majority-owned
subsidiary of the Company. Starting August 12, 2022, Zhigong Lin no longer holds
position as AAGH's Executive Vice President or Chief Executive Officer of GOF.
Zhigong Lin's new position is the advisor/ consultant of the Company. Lin no
longer receives any monthly compensation.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses